

EPM Therapeutics Investment Overview

Synthetic Cannabinoid Acid Derivatives

EPM is a biotechnology company developing novel therapies aiming to address unmet medical needs based on its synthetic cannabinoid acid derivatives. These innovations represent alternative treatment options for millions of patients worldwide covering a wide range of therapeutic conditions.

EPM has **successfully bridged the gap between fully synthetic cannabinoid derivatives as Active Pharmaceutical Ingredients (APIs) and cannabis plant extracts**, resulting in multiple potential development projects for both common and rare diseases. EPM possesses a patented platform of 14 molecules for potential future development or divestment.

Pre-Clinical Studies

EPM **conducted many *in vitro* and *in vivo* preclinical studies, in a wide range of medical indications**, in collaboration with leading researchers and academic institutions. These studies have shown promising results in the following areas:

| | | | | | |
|---|---|---|---|---|---|
|  |  |  |  |  |  |
| Inflammatory skin disorders such as Psoriasis and Atopic Dermatitis | Inflammatory bowel syndrome such as Ulcerative Colitis and Crohn's Disease | Metabolic disorders such as Obesity and Non-Alcoholic Fatty Liver disease | Neuropathic Pain & Osteoarthritis | Major Depressive Disorders | Anxiety and Acute Anticipatory Nausea |

References:

- Zho.Y.F, [et.al](#). An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain, Br. J. Pharmacol. 177, 2712-2725 (2020).
- Hen-Shoval, D. et al. Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. Behav. Brain Res. 351, 1–3 (2018).
- Rock, E. M. et al. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacol. (Berl). 237, 2621-2631 (2020).



Prader Willi Syndrome (PWS) Pre-Clinical Results at a Glance

EPM301 (synthetic cannabidiol acid methyl ester) is our lead development candidate and was recently granted **Orphan Drug Designation by the US FDA** for the treatment of PWS, a rare disease with an estimated market potential of \$US900M to US\$1.2B.

Pre-clinical studies using a Magel 2^{null} mouse model for PWS, demonstrated that **EPM301 effectively reduced body weight and hyperphagia** (food intake) in mice fed a high-fat diet.

In Magel 2^{null} mice fed a standard-diet, EPM301 completely inhibited weight gain and adiposity as seen in increased lean mass and decreased fat mass (Ben-Cnaan, E et al. The metabolic efficacy of a Cannabidiolic Acid (CBDA) derivative in treating diet- and genetic-induced obesity. Int. J. Mol. Sci. 23, 5610-5626 (2022))

Focused Plan Towards an Investigational New Drug Application

EPM seeks a **US\$6M investment to complete pre-clinical testing necessary to file an IND (Investigational New Drug) with the US FDA**. An approved IND filing will substantially increase our valuation and allow us to seek "Series A" funding to take EPM301 in to Phase I thru Phase II Clinical Trials toward an NDA (New Drug Application) to market. Our ODD (Orphan Drug Designation) condenses the requirements for these trials as well as offering us extensions on patent protection.

Strong, Focused and Experienced Team

EPMs Management Team comprises **3 credentialed and highly experienced individuals with over 80 years of global experience in R & D, Financing and Commercialization who are solely** focused on achieving an IND filing for EPM301 in PWS within 5 Quarters from time of investment.



Peter Welburn, PhD. – International experience in R&D roles and general management in Biotech and Pharmaceutical companies. From 2011 to 2014 Dr. Welburn served as the General Manager of LEO Pharma Australia & New Zealand.



Phil Rose – Operational positions in the United States of increasing responsibility in sales, marketing and administration for pharmaceutical companies such as Eli Lilly, GSK and Bausch Health.



Joseph Tam, PhD – Prof. Tam is a world-renowned leader in the field of cannabis-based. He is Head of the Obesity and Metabolism Laboratory at the Hebrew University of Jerusalem and Head Director of the Center of Cannabinoid in Israel.



Jaime Rodriguez – Proven experience in world class companies as a consultant at Bain & Company and as Chief Strategy Officer in publicly traded organizations.